| Population 2015 |
<1 million |
| |
| | | | | |
| Estimates of TB burden*, 2015 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
<0.01 |
(<0.01–<0.01) |
0.41 |
(0.38–0.44) |
| Mortality (HIV+TB only) |
<0.01 |
(<0.01–<0.01) |
0.05 |
(0.01–0.1) |
| Incidence (includes HIV+TB) |
0.13 |
(0.084–0.19) |
21 |
(13–30) |
| Incidence (HIV+TB only) |
<0.01 |
(<0.01–<0.01) |
0.17 |
(0.11–0.25) |
| Incidence (MDR/RR-TB)** |
<0.01 |
(0–<0.01) |
0.5 |
(0–1.2) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2015 |
| |
0-14 years |
> 14 years |
Total |
| Females |
0 |
(0–<0.01) |
0.036 |
(0.01–0.063) |
0.036 |
(<0.01–0.066) |
| Males |
0.01 |
(<0.01–0.014) |
0.084 |
(0.059–0.11) |
0.094 |
(0.065–0.12) |
| Total |
0.01 |
(<0.01–0.013) |
0.12 |
(0.093–0.15) |
0.13 |
(0.084–0.19) |
| |
| | | | | |
| TB case notifications, 2015 |
|
| Total cases notified |
80 |
| Total new and relapse |
80 |
| - % tested with rapid diagnostics at time of diagnosis |
|
| - % with known HIV status |
91% |
| - % pulmonary |
96% |
| - % bacteriologically confirmed among pulmonary |
74% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2015 |
62% (43–95) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 |
0.02 (0.02–0.04) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2015 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
1 |
1% |
| - on antiretroviral therapy |
1 |
100% |
| |
| | | | | |
| Drug-resistant TB care, 2015 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
1
(0–4) |
| Estimated % of TB cases with MDR/RR-TB |
1.9% (0.05–10) |
0% (0–60) |
|
| % notified tested for rifampicin resistance |
71% |
80% |
57 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
0 |
| Laboratory-confirmed cases |
MDR/RR-TB: 1, XDR-TB: 0 |
| Patients started on treatment **** |
MDR/RR-TB: 1, XDR-TB: 0 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2014 |
89% |
113 |
| Previously treated cases, excluding relapse, registered in 2014 |
|
0 |
| HIV-positive TB cases, all types, registered in 2014 |
|
0 |
| MDR/RR-TB cases started on second-line treatment in 2013 |
|
0 |
| XDR-TB cases started on second-line treatment in 2013 |
|
0 |
| |
| | | | | |
| TB preventive treatment, 2015 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
|
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
|
| |
| | | | | |
| TB financing, 2016 |
|
| National TB budget (US$ millions) |
|
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed | | |
| | | | | |